Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery.

bariatric surgery metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease metabolic-associated fatty liver disease recompensation

Journal

Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516

Informations de publication

Date de publication:
21 Jun 2024
Historique:
received: 10 03 2024
revised: 25 05 2024
accepted: 31 05 2024
medline: 23 6 2024
pubmed: 23 6 2024
entrez: 22 6 2024
Statut: aheadofprint

Résumé

The prognosis of patients with decompensated cirrhosis is poor, with significantly increased liver-related mortality rates. With the rising tide of decompensated cirrhosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD), the role of metabolic bariatric surgery (MBS) in achieving hepatic recompensation is garnering increasing attention. However, the complexity of preoperative assessment, the risk of postoperative disease recurrence, and the potential for patients to experience surgical complications of the MBS present challenges. In this opinion article we analyze the potential of MBS to induce recompensation in MASLD-related cirrhosis, discuss the mechanisms by which MBS may affect recompensation, and compare the characteristics of different MBS procedures; we highlight the therapeutic potential of MBS in MASLD-related cirrhosis recompensation and advocate for research in this complex area.

Identifiants

DOI: 10.1016/j.tem.2024.05.009 PMID: 38908982
pubmed: 38908982
pii: S1043-2760(24)00159-0
doi: 10.1016/j.tem.2024.05.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests V.H-G. reports honoraria for lectures from GORE and Cook Medical. The other authors declare no competing interests.

Auteurs

Gong Feng (G)

Xi'an Medical University, Xi'an, China; The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Yu Han (Y)

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Wah Yang (W)

Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Avenue West, Guangzhou, China.

Scott Shikora (S)

Bariatric Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA 02115, USA.

Kamal Mahawar (K)

Bariatric Unit, Sunderland Royal Hospital, Sunderland, SR4 7TP, UK.

Tan To Cheung (TT)

Department of Surgery, the University of Hong Kong, Hong Kong, China.

Giovanni Targher (G)

Department of Medicine, University of Verona, Verona, Italy; Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (VR), Italy.

Christopher D Byrne (CD)

Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK.

Virginia Hernandez-Gea (V)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Barcelona, Spain.

Herbert Tilg (H)

Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria.

Ming-Hua Zheng (MH)

MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China. Electronic address: zhengmh@wmu.edu.cn.

Classifications MeSH